Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to Exhibit Remarkable Growth at a CAGR of 9.2% by 2034 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

24 Feb, 2025, 22:31 GMT

Share this article

Share toX

Share this article

Share toX

The HPV16+ HNSCC market is experiencing robust growth, driven by increasing awareness of HPV-related cancers and the rising incidence of oropharyngeal cancers. The development of immunotherapies and targeted treatments, such as immune checkpoint inhibitors, is fueling market expansion. Additionally, advancements in diagnostic techniques and personalized treatment options are improving patient outcomes, contributing to the market's upward trajectory.

LAS VEGAS, Feb. 24, 2025 /PRNewswire/ -- DelveInsight's HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, HPV16+ HNSCC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Human papillomavirus (HPV) 16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) Market Report

  • According to DelveInsight's analysis, the market size for HPV16+ HNSCC was found to be approximately USD 750 million in the 7MM in 2023.
  • Among the total site-specific cases of HNSCC in the US, the oropharynx was observed to have the highest cases of HNSCC in 2023.
  • As per DelveInsight's estimates, the total incident cases of HPV16+ HNSCC in the 7MM were 45K in 2023.
  • The epidemic of HPV-positive HNSCC will not peak until the 2030s due to the delayed adoption of preventative immunization in pediatric populations. Furthermore, because older age groups are not vaccinated, immunization will not reduce the prevalence of HPV16-positive OPSCC until beyond 2045. Until vaccination coverage does not reaches 100% penetration, the number of patients at risk of advancing on curative therapies is rapidly increasing, despite the fact that a larger proportion of patients have the opportunity of being cured. Therefore, there is an unmet need for improved therapies for these individuals.
  • Leading HPV16+ HNSCC companies developing emerging therapies, such as Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others are developing novel drugs that can be available in the HPV16+ HNSCC market in the coming years. 
  • The promising HPV16+ HNSCC therapies in the pipeline include Petosemtamab (MCLA-158), Zanzalintinib, ISA101b, Versamune HPV (formerly PDS0101), BNT113, CUE-101, Eftilagimod alpha (Efti/IMP321), INO-3112 (MEDI0457), VB10.16 (VB-C-03), Tivumecirnon (FLX475), SCG142, and others.
  • In February 2025, the US Food and Drug Administration (FDA) awarded Breakthrough Therapy designation (BTD) to Merus' petosemtamab in combination with pembrolizumab for the first-line treatment of adult patients with recurrent or metastatic, programmed death-ligand 1 (PD-L1) positive HNSCC with a combined positive score (CPS) ≥ 1. This is petosemtamab's second BTD designation. The first BTD and Fast Track designations were given to petosemtamab in May 2024 and August 2023, respectively, for the treatment of patients with recurrent and/or metastatic HNSCC whose disease has advanced after receiving platinum-based chemotherapy and an anti-PD-1 antibody.
  • In February 2025, PDS Biotechnology confirmed that it would begin its VERSATILE-003 Phase III clinical trial with Versamune HPV plus KEYTRUDA in the first quarter of 2025 as a first-line treatment for recurrent and/or metastatic HPV16-positive HNSCC.
  • In October 2024, Exelixis entered into a clinical development collaboration to evaluate the combination of zanzalintinib with KEYTRUDA in a Phase III pivotal trial for the treatment of patients with HNSCC.
  • The established efficacy of immune checkpoint inhibitors in recurrent and metastatic HNSCC has sparked a growing interest in their neoadjuvant use. Neoadjuvant immunotherapy in HNSCC is promising, as it may reduce the risk of local recurrence and distant metastasis, potentially improving overall survival.

Discover which therapies are expected to grab the major HPV16+ HNSCC market share @ HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Report

HPV16-Positive Head and Neck Squamous Cell Carcinoma Overview

HPV16-positive head and neck squamous cell carcinoma (HPV16+ HNSCC) is a type of cancer that arises in the mucosal surfaces of the oropharynx due to persistent infection with HPV16. Unlike traditional HNSCC, which is strongly linked to tobacco and alcohol use, HPV16+ HNSCC is primarily caused by high-risk HPV infection, often transmitted through oral sexual contact. 

Symptoms may include a persistent sore throat, difficulty swallowing, hoarseness, ear pain, enlarged lymph nodes, and unexplained weight loss. This cancer tends to present with small primary tumors but significant lymph node involvement. Diagnosis involves a combination of physical examination, imaging (CT, MRI, or PET scans), and tissue biopsy. HPV status is confirmed using polymerase chain reaction (PCR) or in situ hybridization (ISH) to detect viral DNA, and p16 immunohistochemistry (IHC) serves as a surrogate marker for HPV-driven malignancy. HPV16+ HNSCC has a better prognosis and response to treatment compared to HPV-negative HNSCC, making accurate diagnosis crucial for therapeutic decisions.

HPV16+ HNSCC Epidemiology Segmentation

The HPV16+ HNSCC epidemiology section provides insights into the historical and current HPV16+ HNSCC patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The HPV16+ HNSCC market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Incident Cases of Head and Neck Cancer
  • Total Incident Cases of HNSCC
  • Site-specific Cases of HNSCC
  • Total Incident Cases of HPV+ HNSCC
  • Total Incident Cases of HPV16+ HNSCC
  • Stage-specific cases of HPV16+ OPSCC
  • Stage-specific cases of HPV16+ Non-OPSCC 

HPV16-Positive Head and Neck Squamous Cell Carcinoma Treatment Market 

The typical treatment for locoregionally advanced HPV16+ HNSCC involves chemoradiation (CRT) or surgery followed by adjuvant therapy. Despite this, recurrence and metastasis rates remain high, especially in later stages. KEYTRUDA and OPDIVO are the main PD-1 inhibitors approved for treating recurrent or metastatic HNSCC. 

In November 2016, the US FDA approved OPDIVO for treating patients with recurrent or metastatic SCCHN who experienced disease progression after platinum-based therapy. In April 2017, the European Commission granted approval for OPDIVO as a monotherapy for adult patients with SCCHN progressing on or after platinum-based treatment. 

In 2021, the UK's NICE recommended OPDIVO for patients with recurrent or metastatic HNSCC who had progression during or after platinum-based chemotherapy. OPDIVO was also approved in Japan in March 2017 for the treatment of relapse or distant metastasis of HNC. In April 2016, BMS announced that the US FDA had given OPDIVO Breakthrough Therapy Designation (BTD) for the potential indication of recurrent or metastatic SCCHN following platinum-based therapy.

In June 2019, the US FDA approved KEYTRUDA for use as a first-line treatment for patients with metastatic or unresectable recurrent HNSCC, including those with HPV. In August 2016, KEYTRUDA received accelerated approval from the US FDA for the treatment of patients with recurrent or metastatic HNSCC who showed disease progression following platinum-based chemotherapy, also including those with HPV. 

In November 2019, Merck announced that the European Commission had approved KEYTRUDA as a first-line treatment for metastatic or unresectable recurrent HNSCC in patients whose tumors express PD-L1 (CPS ≥1). In December 2019, Merck also reported that the Japan Pharmaceuticals and Medical Devices Agency (PMDA) had approved KEYTRUDA, both in combination with chemotherapy and as a monotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck cancer (HNC).

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, though only around 20% of patients respond, and HPV status does not significantly affect the response. Currently, there are no treatments specifically approved for HPV16+ cancers. 

To know more about HPV16+ HNSCC treatment guidelines, visit @ HPV16-Positive Head and Neck Squamous Cell Carcinoma Management 

HPV16+ HNSCC Pipeline Therapies and Key Companies

  • Zanzalintinib (XL092): Exelixis
  • Eftilagimod alpha (Efti/IMP321): Immutep/Merck Sharp & Dohme
  • ISA101b: ISA Pharmaceuticals and Regeneron Pharmaceuticals
  • Versamune HPV (PDS0101): PDS Biotechnology and Merck
  • BNT113: BioNTech
  • INO-3112 (MEDI0457): Inovio Pharmaceuticals and MedImmune
  • CUE-101: Cue Biopharma
  • VB10.16 (VB-C-03): Nykode Therapeutics
  • Tivumecirnon (FLX475): RAPT Therapeutics

Discover more about HPV16+ HNSCC drugs in development @ HPV16+ HNSCC Clinical Trials 

HPV16+ HNSCC Market Dynamics

The HPV16+ HNSCC market dynamics are expected to change in the coming years. The increasing incidence of HPV-related cancers, particularly HPV16+ HNSCC, is fueling demand for targeted therapies and preventive vaccines. As awareness grows about the link between HPV16 and HNSCC, there is a rising focus on early diagnosis and preventive measures, including vaccination programs. The development of novel immunotherapies and targeted treatments aimed specifically at HPV16+ cancers is another significant driver, offering improved efficacy over conventional chemotherapy and radiation. 

Additionally, the growing prevalence of HPV infections, especially in younger populations, is prompting healthcare providers and researchers to invest in better screening methods and treatment options. Government support, regulatory approvals, and increased healthcare expenditure in oncology further contribute to the market's growth, creating opportunities for new treatments to emerge in this rapidly evolving space.

Apart from this, the landscape is highly competitive, with key players like PDS Biotechnology, ISA Pharmaceuticals, Immutep, BioNTech, Cue Pharma, and others driving innovative strategies to improve efficacy and broaden treatment options for HPV16+ HNSCC, offering new hope for patients with limited current alternatives.

Furthermore, potential therapies are being investigated for the treatment of HPV16+ HNSCC, and it is safe to predict that the treatment space will significantly impact the HPV16+ HNSCC market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the HPV16+ HNSCC market in the 7MM.

Currently, a number of HPV-targeted vaccines in HNSCC are being studied; the most encouraging findings have been seen when used in combination with checkpoint inhibitors as a first-line treatment for recurrent or metastatic disease. Although there are some studies looking at these vaccines in treatment-refractory patients, the response rate in that population tends to be lower. Additionally, ongoing trials are investigating the use of therapeutic vaccines without immunotherapy.

However, several factors may impede the growth of the HPV16+ HNSCC market. One of the primary challenges is the complex and heterogeneous nature of HNSCC, which can make it difficult to develop targeted therapies that work universally across patient populations. Additionally, while HPV16+ HNSCC is linked to a distinct patient subgroup, there is a lack of widespread screening, resulting in late-stage diagnoses that reduce the efficacy of available treatments. Regulatory hurdles also present obstacles, as the approval process for new therapies often involves lengthy clinical trials and extensive safety assessments. 

Moreover, HPV16+ HNSCC treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the HPV16+ HNSCC market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HPV16+ HNSCC market growth.

HPV16+            HNSCC    Market              Report
Metrics

Details

Study Period

2020–2034

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

HPV16+             HNSCC Market CAGR    

(2020-2034)

9.2 %

HPV16+            HNSCC  Market Size in 2023

USD 750 million

Key HPV16+      HNSCC Companies

Bristol Myers Squibb, Merck, Ono Pharmaceutical, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others

Key                     Pipeline HPV16+              HNSCC Therapies

KEYTRUDA, OPDIVO, Petosemtamab (MCLA-158), Zanzalintinib, ISA101b, Versamune HPV, BNT113, CUE-101, Eftilagimod alpha (Efti/IMP321), INO-3112 (MEDI0457), VB10.16 (VB-C-03), Tivumecirnon (FLX475), SCG142, Versamune HPV + PDS01ADC + Bintrafusp alfa and others

Scope of the HPV16+ HNSCC Market Report

  • Therapeutic Assessment: HPV16+ HNSCC current marketed and emerging therapies
  • HPV16+ HNSCC Market Dynamics: Key Market Forecast Assumptions of Emerging HPV16+ HNSCC Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, HPV16+ HNSCC Market Access and Reimbursement

Download the report to understand which factors are driving HPV16+ HNSCC market trends @ HPV16+ HNSCC Market Trends

Table of Contents

1

Key Insights

2

Report Introduction

3

Executive Summary of HPV 16-Positive HNSCC

4

Key Events

5

Epidemiology and Market Forecast Methodology

6

HPV16+ HNSCC Market Overview at a Glance

6.1

Market Share (%) Distribution of HPV16+ HNSCC by Line of therapy (LoT) in 2020

6.2

Market Share (%) Distribution of HPV16+ HNSCC by Line of therapy (LoT) in 2034

7

Disease Background and Overview

7.1

Introduction

7.2

Classification of HNSCC

7.3

Signs and Symptoms

7.4

Causes

7.5

HPV in HNSCC

7.5.1

HPV-positive HNSCC

7.5.2

Genomic Alterations and Key Pathways

7.6

Diagnosis

7.6.1

Diagnostic Tools and Applied Algorithm in HNSCC Classification

7.6.2

HPV Biomarkers in Body Fluids

7.7

Staging

7.8

Diagnosis Algorithm

7.9

Treatment and Management

7.9.1

Treatment Algorithm

7.1

Treatment Guidelines

7.10.1

American Society for Radiation Oncology (ASTRO) Clinical Practice Guideline

7.10.2

National Comprehensive Cancer Network (NCCN) Guidelines 

7.10.3

EHNS–ESMO–ESTRO Clinical Practice Guidelines 

7.10.4

Spanish Society of Medical Oncology (SEOM) Clinical Guidelines 

8

Epidemiology and Patient Population

8.1

Key Findings

8.2

Assumptions and Rationale

8.3

Total Incident Cases of Head and Neck Cancer in the 7MM

8.4

HPV+ HNSCC Cases in the 7MM

8.5

Total Incident Cases of HPV16+ HNSCC in the 7MM

8.6

The United States

8.6.1

Total Incident Cases of HNSCC in the US

8.6.2

Site-specific Cases of HNSCC in the US

8.6.3

HPV+ HNSCC Cases in the US

8.6.4

Total Incident Cases of HPV16+ HNSCC in the US

8.6.5

Stage-specific Cases of HPV16+ OPSCC in the US

8.6.6

Stage-specific Cases of HPV16+ Non-OPSCC in the US

8.7

EU4 and the UK

8.7.1

Total Incident Cases of HNSCC in EU4 and the UK

8.7.2

Site-specific Cases of HNSCC in EU4 and the UK

8.7.3

HPV+ HNSCC Cases in EU4 and the UK

8.7.4

Total Incident Cases of HPV16+ HNSCC in EU4 and the UK

8.7.5

Stage-specific Cases of HPV16+ OPSCC in EU4 and the UK

8.7.6

Stage-specific Cases of HPV16+ Non-OPSCC in EU4 and the UK

8.8

Japan

8.8.1

Total Incident Cases of HNSCC in Japan

8.8.2

Site-specific Cases of HNSCC in Japan

8.8.3

HPV+ HNSCC Cases in Japan

8.8.4

Total Incident Cases of HPV16+ HNSCC in Japan

8.8.5

Stage-specific Cases of HPV16+ OPSCC in Japan

8.8.6

Stage-specific Cases of HPV16+ Non-OPSCC in Japan

9

Patient Journey

10

Key Endpoints

11

Marketed Drugs

11.1

Key Competitors

11.2

OPDIVO (nivolumab): Bristol Myers Squibb

11.2.1

Product Description

11.2.2

Regulatory Milestones

11.2.3

Other Developmental Activities

11.2.4

Safety and Efficacy

11.2.5

Analyst's Views

11.3

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

11.3.1

Product Description

11.3.2

Regulatory Milestones

11.3.3

Other Developmental Activities

11.3.4

Safety and Efficacy

11.3.5

Analyst's Views

12

Emerging Therapies

12.1

Key Cross Competition

12.2

Zanzalintinib (XL092): Exelixis

12.2.1

Product Description

12.2.2

Other Development Activities

12.2.3

Clinical Developmental

12.2.4

Analyst Views

12.3

Eftilagimod alpha (Efti/IMP321): Immutep/Merck Sharp & Dohme

12.3.1

Product Description

12.3.2

Other Developmental Activities

12.3.3

Clinical Developmental

12.3.4

Safety and Efficacy

12.3.5

Analyst Views

12.4

ISA101b: ISA Pharmaceuticals and Regeneron Pharmaceuticals

12.4.1

Product Description

12.4.2

Other Development Activity

12.4.3

Clinical Development

12.4.4

Safety and Efficacy

12.4.5

Analyst Views

12.5

Versamune HPV (PDS0101): PDS Biotechnology and Merck

12.5.1

Product Description

12.5.2

Other Development Activity

12.5.3

Clinical Development

12.5.4

Safety and Efficacy

12.5.5

Analyst Views

12.6

BNT113: BioNTech

12.6.1

Product Description

12.6.2

Other Development Activity

12.6.3

Clinical Development

12.6.4

Safety and Efficacy

12.6.5

Analyst Views

12.7

INO-3112 (MEDI0457): Inovio Pharmaceuticals and MedImmune

12.7.1

Product Description

12.7.2

Other Development Activity

12.7.3

Clinical Development

12.7.4

Safety and Efficacy

12.7.5

Analyst Views

12.8

CUE-101: Cue Biopharma

12.8.1

Product Description

12.8.2

Other Developmental Activities

12.8.3

Clinical Development

12.8.4

Safety and Efficacy

12.8.5

Analyst Views

12.9

VB10.16 (VB-C-03): Nykode Therapeutics

12.9.1

Product Description

12.9.2

Other Development Activity

12.9.3

Clinical Development

12.9.4

Analyst Views

12.1

Tivumecirnon (FLX475): RAPT Therapeutics

12.10.1

Product Description

12.10.2

Other Development Activities

12.10.3

Clinical Development

12.10.4

Safety and Efficacy

13

HPV16+ HNSCC: Seven Major Market Analysis

13.1

Key Findings

13.2

Market Outlook

13.3

Conjoint Analysis

13.4

Key Market Forecast Assumptions

13.4.1

Cost Assumptions and Rebate

13.4.2

Pricing Trends

13.4.3

Analogue Assessment

13.4.4

Launch Year and Therapy Uptake

13.5

Total Market Size of HPV16+ HNSCC in the 7MM

13.6

The United States

13.6.1

Total Market Size of HPV16+ HNSCC in the US

13.6.2

Market Size of HPV16+ HNSCC by Therapies in the US

13.7

EU4 and the UK

13.7.1

Total Market Size of HPV16+ HNSCC in EU4 and the UK

13.7.2

Market Size of HPV16+ HNSCC by Therapies in EU4 and the UK

13.8

Japan

13.8.1

Total Market Size of HPV16+ HNSCC in Japan

13.8.2

The Market Size of HPV16+ HNSCC by Therapies in Japan

14

Unmet Needs

15

SWOT Analysis

16

KOL Views

17

Market Access and Reimbursement

17.1

United States

17.1.1

Centre for Medicare & Medicaid Services (CMS)

17.2

EU4 and the UK

17.2.1

Germany

17.2.2

France

17.2.3

Italy

17.2.4

Spain

17.2.5

United Kingdom

17.3

Japan

17.3.1

MHLW

17.4

HPV16+ HNSCC Market Access and Reimbursement

18

Appendix

18.1

Bibliography

18.2

Report Methodology

19

DelveInsight Capabilities

20

Disclaimer

21

About DelveInsight

Related Reports

HPV16+ Cancers Market

HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV16+ cancers companies, including GlaxoSmithKline, PDS Biotechnology, Merck, Cue Biopharma, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Vaccibody AS, Transgene, Innovio Pharma, Hookipa Pharma, Roche Pharma AG, Invectys, BioNTech, Advaxis, Inc., Precigen, among others.

Head and Neck Squamous Cell Carcinoma Market

Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNSCC companies, including VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals, among others.

Recurrent Head and Neck Squamous Cell Carcinoma Pipeline

Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent HNSCC companies, including AstraZeneca, Astellas, GlaxoSmithKline, Boehringer Ingelheim, Merck, among others.

Human Papillomavirus Market

Human Papillomavirus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com 
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

Modal title

Also from this source

MAC Lung Disease Market Poised for Growth Across the 7MM During the Forecast Period (2025-2034) Amid Rising Prevalence and New Therapeutic Solutions | DelveInsight

MAC Lung Disease Market Poised for Growth Across the 7MM During the Forecast Period (2025-2034) Amid Rising Prevalence and New Therapeutic Solutions | DelveInsight

Mycobacterium avium Complex (MAC) refers to a group of bacteria, primarily Mycobacterium avium and Mycobacterium intracellulare, that are responsible ...

Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight

Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Intra-tumoral Cancer Therapies Market report includes a comprehensive understanding of current treatment practices, emerging...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.